Synovial sarcoma X breakpoint 2 peptide–major histocompatibility complex (SSX2-pMHC)

Synovial sarcoma X breakpoint 2 (SSX2) is a member of the cancer-testis antigen (CTA) family, characterized by restricted expression in the testis and high expression in various malignant tissues (UniProt: P35232). The SSX2 peptide–MHC complex is formed when intracellular SSX2 proteins are processed by the proteasome into short peptides, which are then transported to the endoplasmic reticulum and loaded onto Major Histocompatibility Complex (MHC) class I molecules, most notably HLA-A*02:01 (PubMed: 10833474). This complex is displayed on the tumor cell surface, where it serves as a specific ligand for T-cell receptors (TCRs). Because SSX2 is not expressed in normal adult somatic tissues, the SSX2-pMHC complex is an ideal target for adoptive cell therapies, such as TCR-engineered T-cells (TCR-T), which are designed to recognize and kill cells presenting these specific antigens (ClinicalTrials.gov: NCT02621021). Therapeutic development focuses on high-affinity TCRs and TCR-like antibodies to exploit this tumor-specific presentation for treating synovial sarcoma, melanoma, and other SSX2-expressing solid tumors (PubMed: 15150594).

Other names

SSX2-HLA complexSSX2 peptide-HLA-A*02:01 complexSSX2 antigen-MHC complexSSX2-HLA-A2Cancer-testis antigen SSX2-pMHC

T-cell receptor (TCR) mediated recognition of the specific SSX2 peptide presented by MHC class I molecules, leading to targeted T-cell activation and cytotoxic lysis of tumor cells.